Placebo to doravirine/ islatravir
Sponsors
Merck Sharp & Dohme LLC
Conditions
HIV-1 Infection
Phase 3
A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Naïve Participants
WithdrawnCTIS2022-502099-22-00
Target: 124Updated: 2023-05-02
A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Naïve Participants
Active, not recruitingCTIS2022-502099-22-01
Start: 2024-04-29Target: 82Updated: 2025-08-22